Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Running, not enrolling · Phase 3
Conditions studied: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
In brief
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).
Key facts
- Study ID
- NCT05840211
- Run by
- Gilead Sciences
- People needed
- 654
- Starts
- 2023-05-08
- Expected to finish
- 2028-04-01
- Last updated by the study team
- 2025-10-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Second Hospital of Jilin University — Jilin Sheng, China
- Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers — Chandler, Arizona, United States
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California, United States
- Stanford Cancer Institute — Palo Alto, California, United States
- University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- Rocky Mountain Cancer Centers, LLP — Littleton, Colorado, United States
- Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut, United States
- Investigational Drug Services, AdventHealth Orlando — Altamonte Springs, Florida, United States
- Florida Cancer Specialists — Brooksville, Florida, United States
- Florida Cancer Specialist — Leesburg, Florida, United States
- Florida Cancer Specialist — St. Petersburg, Florida, United States
- Piedmont Cancer Institute — Atlanta, Georgia, United States
- Georgia Cancer Specialist - Annex — Atlanta, Georgia, United States
- Northwest Georgia Oncology Centers — Marietta, Georgia, United States
- The University of Kansas Hospital — Kansas City, Kansas, United States
- Hematology Oncology Clinic — Baton Rouge, Louisiana, United States
- Saint Luke's Cancer Institute — Kansas City, Missouri, United States
- David C. Pratt Cancer Center — St Louis, Missouri, United States
- Astera Cancer Care — East Brunswick, New Jersey, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio, United States
- Penn State Cancer Institute — Hershey, Pennsylvania, United States
- The Nanchang Third Hospital — Jiangxi, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.